Evidence map›Paper›PMID 41673585›Full record

ArticleBMC cancer2026

Increased cytoplasmic and nuclear S100A6 expression is associated with improved prognosis in ovarian cancer.

Aruba Farooq, Evren M Akyuz, Brandon Wq Cheah, Suha Deen, Stewart G Martin, Mattéa J Finelli, Sarah Storr, Alan McIntyre

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Silver-LoadedMarine drugs · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Aruba FarooqHypoxia and Acidosis Research Group, Centre for Cancer Sciences, School of Medicine, University of Nottingham Biodiscovery Institute, Nottingham, UK.
Evren M AkyuzHypoxia and Acidosis Research Group, Centre for Cancer Sciences, School of Medicine, University of Nottingham Biodiscovery Institute, Nottingham, UK.
Brandon Wq CheahHypoxia and Acidosis Research Group, Centre for Cancer Sciences, School of Medicine, University of Nottingham Biodiscovery Institute, Nottingham, UK.
Suha DeenDepartment of Pathology, Queen's Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Stewart G MartinNottingham Breast Cancer Research Centre, School of Medicine, University of Nottingham Biodiscovery Institute, Nottingham, UK.
Mattéa J FinelliSchool of Medicine, University of Nottingham Biodiscovery Institute, Nottingham, UK.
Sarah StorrNottingham Breast Cancer Research Centre, School of Medicine, University of Nottingham Biodiscovery Institute, Nottingham, UK.
Alan McIntyreHypoxia and Acidosis Research Group, Centre for Cancer Sciences, School of Medicine, University of Nottingham Biodiscovery Institute, Nottingham, UK. alan.mcintyre@nottingham.ac.uk.

Funding

Wellcome Trust [218466/Z/19/Z], studentship [319465/Z/24/Z]
6 · The paper itself

Abstract

backgroundOvarian cancer is one of the most common gynaecological cancers affecting more than 300,000 women worldwide each year. S100 calcium-binding protein A6 (S100A6) is a member of the S100 family of calcium-binding proteins. Upon activation by calcium (Ca2+) signalling, S100A6 regulates numerous cellular processes including cell proliferation and metastasis. The role of S100A6 is well established across multiple tumour types where increased S100A6 expression contributes to tumourigenesis and worse patient outcome. However, the role of S100A6 in ovarian cancer is not well established.

methodsThe impact of cytoplasmic and nuclear S100A6 expression on overall survival and clinicopathological criteria was investigated in 462 ovarian tumours by immunohistochemistry. Additionally, S100A6 expression in an ovarian cancer cohort from The Cancer Genome Atlas (TCGA) PanCancer dataset (n = 299) was evaluated and associations with overall survival and progression-free survival were identified.

resultsImmunohistochemical staining revealed that high cytoplasmic expression of S100A6 was significantly associated with better overall survival (p = 0.014). Additionally, high nuclear expression was significantly associated with better overall survival (p = 0.036). In contrast, analysis of mRNA S100A6 suggests no significant association of mRNA levels for overall survival (p = 0.903) and progression free survival (p = 0.278).

conclusionsOur data provides novel insights regarding the clinical implications of S100A6 expression in ovarian cancer, providing strong rationale for functional investigations of S100A6 in ovarian cancer.

Indexed as

Biomarkers, TumorCell Cycle ProteinsCell NucleusCytoplasmOvarian NeoplasmsS100 Calcium Binding Protein A6AdultAgedFemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryMiddle AgedPrognosisBiomarkers, TumorCell Cycle ProteinsS100A6 protein, humanS100 Calcium Binding Protein A6Ovarian cancerS100A6Survival

Identifiers

PMID41673585
PMCPMC12998080

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.